Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUOPANC: cRGD-ZW800-1 for NIR Imaging in Pancreatic and Bile Duct Tumors
NCT05518071Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of cRGD-ZW800-1 in pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), sponsored by Leiden University Medical Center. Started Nov 2022; status: completed.
02
Drugs
cRGD-ZW800-1
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05518071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518071.